FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2794018905> ?p ?o ?g. }

• W2794018905 endingPage "366" @default.
• W2794018905 startingPage "363" @default.
• W2794018905 abstract "Background: Colchicine is the mainstay of the treatment of familial Mediterranean fever (FMF). However, 10% of FMF patients do not respond well to colchicine. Efficacy of interleukin (IL)-1 inhibitors in reducing attacks have been demonstrated in colchicine-resistant FMF (crFMF) patients recently. Colchicine is still the only approved drug for the prevention of amyloidosis in FMF and utility of IL-1 inhibitors in crFMF cases who already has amyloidosis remain to be elucidated. Herein, we evaluated efficacy and safety of IL-1 inhibitors in patients with crFMF-associated AA amyloidosis in a relatively large single center study. Methods: Medical records of FMF patients complicated with AA amyloidosis in our dedicated FMF center were retrospectively reviewed and those patients who ever treated with IL-1 inhibitors were enrolled into the study. Patient global, physician global assessments (on 0–10 cm visual analog scale), C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), serum creatinine and 24-h urinary protein excretion values for each visit were recruited from computer-based hospital records. Treatment response of patients were assessed with clinical symptoms, serum albumin, CRP and ESR values. Renal outcome parameters were analyzed on those not receiving renal replacement therapy. Results: Seventeen patients were identified with crFMF-amyloidosis that ever treated with IL-1 inhibitors. Background colchicine therapy was continued in all patients in maximal-tolerated dose along with IL-1 inhibitors. All patients benefit from IL-1 antagonists assessed by patient and physician global assessments. Inflammatory markers, CRP and ESR, were significantly reduced in all and normalized in 12 out of 17 patients. More importantly, the amount of proteinuria was remarkably improved following IL-1 inhibitor therapy (1606 mg/day to 519 mg/day, p = .008). Both anakinra and canakinumab were well-tolerated without severe side effects. All patients were initially treated with anakinra but switched to canakinumab in seven patients (one leukopenia, four injection site reaction, two inefficacy). Conclusion: We evaluated the clinical and laboratory responses to IL-1 inhibitors in crFMF-associated amyloidosis patients. We found significant decreases in CRP, ESR and proteinuria after IL-1 inhibitor therapy. This study confirmed that IL-1 inhibitors are effective for controlling attacks and inflammatory activity in FMF patients complicated with AA amyloidosis. Moreover, they reduce or stabilize amount of proteinuria and preserve renal function in short-term follow-up. Prolonged prospective clinical trials are warranted to assess their long-term efficacy in this particular patient group." @default.
• W2794018905 created "2018-03-29" @default.
• W2794018905 creator A5011026117 @default.
• W2794018905 creator A5027090208 @default.
• W2794018905 creator A5027801988 @default.
• W2794018905 creator A5029585134 @default.
• W2794018905 creator A5031139703 @default.
• W2794018905 creator A5035790186 @default.
• W2794018905 creator A5053780651 @default.
• W2794018905 creator A5072082690 @default.
• W2794018905 date "2018-04-27" @default.
• W2794018905 modified "2023-10-14" @default.
• W2794018905 title "Efficacy and safety of interleukin-1 inhibitors in familial Mediterranean fever patients complicated with amyloidosis" @default.
• W2794018905 cites W1524368767 @default.
• W2794018905 cites W1983961294 @default.
• W2794018905 cites W2027227375 @default.
• W2794018905 cites W2034352078 @default.
• W2794018905 cites W2051818440 @default.
• W2794018905 cites W2057433251 @default.
• W2794018905 cites W2071257219 @default.
• W2794018905 cites W2141257085 @default.
• W2794018905 cites W2180891493 @default.
• W2794018905 cites W2292136509 @default.
• W2794018905 cites W2324640604 @default.
• W2794018905 cites W2464113330 @default.
• W2794018905 cites W2556420285 @default.
• W2794018905 cites W4229832897 @default.
• W2794018905 doi "https://doi.org/10.1080/14397595.2018.1457469" @default.
• W2794018905 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29578360" @default.
• W2794018905 hasPublicationYear "2018" @default.
• W2794018905 type Work @default.
• W2794018905 sameAs 2794018905 @default.
• W2794018905 citedByCount "41" @default.
• W2794018905 countsByYear W27940189052018 @default.
• W2794018905 countsByYear W27940189052019 @default.
• W2794018905 countsByYear W27940189052020 @default.
• W2794018905 countsByYear W27940189052021 @default.
• W2794018905 countsByYear W27940189052022 @default.
• W2794018905 countsByYear W27940189052023 @default.
• W2794018905 crossrefType "journal-article" @default.
• W2794018905 hasAuthorship W2794018905A5011026117 @default.
• W2794018905 hasAuthorship W2794018905A5027090208 @default.
• W2794018905 hasAuthorship W2794018905A5027801988 @default.
• W2794018905 hasAuthorship W2794018905A5029585134 @default.
• W2794018905 hasAuthorship W2794018905A5031139703 @default.
• W2794018905 hasAuthorship W2794018905A5035790186 @default.
• W2794018905 hasAuthorship W2794018905A5053780651 @default.
• W2794018905 hasAuthorship W2794018905A5072082690 @default.
• W2794018905 hasConcept C126322002 @default.
• W2794018905 hasConcept C198451711 @default.
• W2794018905 hasConcept C2776636253 @default.
• W2794018905 hasConcept C2777007455 @default.
• W2794018905 hasConcept C2778143017 @default.
• W2794018905 hasConcept C2779134260 @default.
• W2794018905 hasConcept C2779537928 @default.
• W2794018905 hasConcept C2779725882 @default.
• W2794018905 hasConcept C2779951007 @default.
• W2794018905 hasConcept C2780306776 @default.
• W2794018905 hasConcept C2781228260 @default.
• W2794018905 hasConcept C71924100 @default.
• W2794018905 hasConcept C90924648 @default.
• W2794018905 hasConceptScore W2794018905C126322002 @default.
• W2794018905 hasConceptScore W2794018905C198451711 @default.
• W2794018905 hasConceptScore W2794018905C2776636253 @default.
• W2794018905 hasConceptScore W2794018905C2777007455 @default.
• W2794018905 hasConceptScore W2794018905C2778143017 @default.
• W2794018905 hasConceptScore W2794018905C2779134260 @default.
• W2794018905 hasConceptScore W2794018905C2779537928 @default.
• W2794018905 hasConceptScore W2794018905C2779725882 @default.
• W2794018905 hasConceptScore W2794018905C2779951007 @default.
• W2794018905 hasConceptScore W2794018905C2780306776 @default.
• W2794018905 hasConceptScore W2794018905C2781228260 @default.
• W2794018905 hasConceptScore W2794018905C71924100 @default.
• W2794018905 hasConceptScore W2794018905C90924648 @default.
• W2794018905 hasIssue "2" @default.
• W2794018905 hasLocation W27940189051 @default.
• W2794018905 hasLocation W27940189052 @default.
• W2794018905 hasOpenAccess W2794018905 @default.
• W2794018905 hasPrimaryLocation W27940189051 @default.
• W2794018905 hasRelatedWork W1476192100 @default.
• W2794018905 hasRelatedWork W1765607015 @default.
• W2794018905 hasRelatedWork W1977930924 @default.
• W2794018905 hasRelatedWork W1991378232 @default.
• W2794018905 hasRelatedWork W2012145456 @default.
• W2794018905 hasRelatedWork W2106284313 @default.
• W2794018905 hasRelatedWork W2896149337 @default.
• W2794018905 hasRelatedWork W2999594830 @default.
• W2794018905 hasRelatedWork W3008408616 @default.
• W2794018905 hasRelatedWork W4386386689 @default.
• W2794018905 hasVolume "29" @default.
• W2794018905 isParatext "false" @default.
• W2794018905 isRetracted "false" @default.
• W2794018905 magId "2794018905" @default.
• W2794018905 workType "article" @default.